Novo Nordisk

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. 

CEO
Maziar Mike Doustdar
CEOMaziar Mike Doustdar
Employees
68,794
Employees68,794
Headquarters
Bagsværd, Capital Region
HeadquartersBagsværd, Capital Region
Founded
1923
Founded1923
Employees
68,794
Employees68,794

NVO Key Statistics

Market cap
171.71B
Market cap171.71B
Price-Earnings ratio
11.41
Price-Earnings ratio11.41
Dividend yield
3.09%
Dividend yield3.09%
Average volume
28.02M
Average volume28.02M
High today
$39.85
High today$39.85
Low today
$38.18
Low today$38.18
Open price
$39.20
Open price$39.20
Volume
20.83M
Volume20.83M
52 Week high
$82.57
52 Week high$82.57
52 Week low
$35.85
52 Week low$35.85

NVO News

Simply Wall St 9h
Novo Nordisk Valuation Check After Recent Share Price Weakness And Long Term Return Pressures

Advertisement Recent share performance and business snapshot Novo Nordisk (NVO) has had a mixed run recently, with the stock showing a 2.7% one day decline al...

Novo Nordisk Valuation Check After Recent Share Price Weakness And Long Term Return Pressures
TipRanks 11h
Dr. Reddy’s clarifies Delhi High Court ruling on semaglutide exports

Dr. Reddy’s Laboratories Ltd. ( (IN:DRREDDY) ) has issued an update. Dr. Reddy’s Laboratories has clarified media reports that the Delhi High Court has allowed...

Barron's 13h
Hims & Hers Stock Upgraded After Novo Nordisk Agreement. Why It Isn’t a Buy Yet.

Healthcare Hims & Hers Stock Upgraded After Novo Nordisk Agreement. Why It Isn’t a Buy Yet. In this article HIMS NVO SPX Hims & Hers Health agreed to sell Novo...

Hims & Hers Stock Upgraded After Novo Nordisk Agreement. Why It Isn’t a Buy Yet.

Analyst ratings

64%

of 33 ratings
Buy
30.3%
Hold
63.6%
Sell
6.1%

More NVO News

TipRanks 13h
Novo Nordisk Stock Dives After FDA Scolds the Pharma Giant

Shares of Novo Nordisk (NVO) are down 4% in afternoon trading on March 10 after the U.S. Food and Drug Administration issued a sharp rebuke of the European phar...

The Wall Street Journal 15h
FDA Warns Novo Nordisk of Unreported Side Effects Tied to GLP-1 Patients

Novo Nordisk has battled for dominance in the rapidly growing weight-loss and diabetes drug market. Tom Little/Reuters Novo Nordisk NOVO.B -2.97 %decrease; red...

FDA Warns Novo Nordisk of Unreported Side Effects Tied to GLP-1 Patients
Barron's 15h
Wall Street Gets Less Bearish on Hims & Hers After Novo Nordisk Truce. Stock Gains Could Still Be Limited.

Healthcare Wall Street Gets Less Bearish on Hims & Hers After Novo Nordisk Truce. Stock Gains Could Still Be Limited. In this article HIMS NVO SPX Hims & Hers H...

Wall Street Gets Less Bearish on Hims & Hers After Novo Nordisk Truce. Stock Gains Could Still Be Limited.
24/7 Wall St. 17h
Wall Street Pulls Back on Novo Nordisk and Jefferies While Talkspace Heads for Exit

Wall Street Pulls Back on Novo Nordisk and Jefferies While Talkspace Heads for Exit Quick Read Novo Nordisk (NVO) cut to Hold, $42 target, down 53.14% past yea...

Wall Street Pulls Back on Novo Nordisk and Jefferies While Talkspace Heads for Exit
Sherwood News 17h
Hims continues to rise on analyst upgrades following its Novo Nordisk partnership

Hims continues to rise on analyst upgrades following its Novo Nordisk partnership Shares of telehealth company Hims & Hers climbed Tuesday as analysts upgraded...

Hims continues to rise on analyst upgrades following its Novo Nordisk partnership
TipRanks 18h
FDA posts warning letter sent to Novo over semaglutide marketing

In a warning letter to Novo Nordisk (NVO) regarding its Plainsboro, NJ plant, the FDA said, “Specifically, you and your contractors inappropriately invalidated...

TipRanks 19h
Novo Nordisk’s Hims deal helps with commercial headwind, says BMO Capital

BMO Capital keeps a Market Perform rating and $45 price target on Novo Nordisk (NVO). The company’s agreement with Hims & Hers (HIMS) to partner on sale of bran...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.